Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Quercetin for COVID-19: real-time meta analysis of 9 studies
Covid Analysis, June 23, 2022, DRAFT
https://c19quercetin.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 94% 0.06 [0.00-1.00] ICU 0/76 8/76 Di Pierro (RCT) 68% 0.32 [0.14-0.70] hosp. 7/76 22/76 Di Pierro (RCT) 67% 0.33 [0.01-7.74] death 0/21 1/21 Di Pierro (RCT) 67% 0.33 [0.01-7.74] ICU 0/21 1/21 Di Pierro (RCT) 67% 0.33 [0.01-7.74] hosp. 0/21 1/21 Di Pierro (RCT) 74% 0.26 [0.12-0.57] viral+ 5/21 19/21 Di Pierro (RCT) 89% 0.11 [0.01-1.94] viral+ 0/21 4/21 Khan (RCT) 33% 0.67 [0.37-1.19] no recov. 10/25 15/25 CT​1 Khan (RCT) 39% 0.61 [0.43-0.87] no recov. 25 (n) 25 (n) CT​1 Khan (RCT) 50% 0.50 [0.30-0.84] viral+ 10/25 20/25 CT​1 Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Onal (RCT) 94% 0.06 [0.00-0.98] ICU 0/49 14/380 CT​1 Onal (RCT) 78% 0.22 [0.03-1.58] no disch. 1/49 35/380 CT​1 Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Zupanets (RCT) 18% 0.82 [0.68-0.98] recov. time 99 (n) 101 (n) Shohan (RCT) 86% 0.14 [0.01-2.65] death 0/30 3/30 Shohan (RCT) 40% 0.60 [0.16-2.29] ICU 3/30 5/30 Shohan (RCT) 32% 0.68 [0.47-0.98] recov. time 30 (n) 30 (n) Arslan (RCT) 92% 0.08 [0.01-0.79] cases 1/71 9/42 CT​1 Margolin 94% 0.06 [0.00-0.93] cases 0/53 9/60 CT​1 Margolin 81% 0.19 [0.04-0.80] cases 2/53 12/60 CT​1 Rondanelli (DB RCT) 93% 0.07 [0.01-0.91] symp. case 1/60 4/60 quercetin COVID-19 outcomes c19quercetin.com Jun 2022 1 CT: study uses combined treatment Favors quercetin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit